Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer

被引:24
作者
Heinzer, H [1 ]
Huland, E [1 ]
Huland, H [1 ]
机构
[1] Univ Hamburg, Clin Eppendorf, Dept Urol, D-20246 Hamburg, Germany
基金
英国医学研究理事会;
关键词
D O I
10.1007/s003450000191
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
We review the current literature on systemic therapy for patients with metastatic renal cell carcinoma. Metastatic renal cell carcinoma remains highly resistant to chemotherapy and hormonal agents not justifying its use as a single agent. Interleukin-2 immunotherapy is the most effective treatment for metastatic renal cell carcinoma available today. There is evidence that interleukin-2 improves survival and yields longlasting remissions in selected patients the optimal dose and schedule still need to be defined. Response rates in patients treated with subcutaneous interleukin-2 are similar to those achieved with high-dose bolus intravenous applications. Questions remain concerning quality of life and benefit-to-risk ratio with respect to immunotherapy in individual patients. Different routes of administration of interleukin-2 such as local application, promise to improve quality of life and survival times.
引用
收藏
页码:111 / 119
页数:9
相关论文
共 122 条
[1]   HIGH-DOSE RECOMBINANT INTERLEUKIN-2 ALONE - A REGIMEN WITH LIMITED ACTIVITY IN THE TREATMENT OF ADVANCED RENAL-CELL CARCINOMA [J].
ABRAMS, JS ;
RAYNER, AA ;
WIERNIK, PH ;
PARKINSON, DR ;
EISENBERGER, M ;
ARONSON, FR ;
GUCALP, R ;
ATKINS, MB ;
HAWKINS, MJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (14) :1202-1206
[2]   RANDOMIZED PHASE-II TRIAL OF HIGH-DOSE INTERLEUKIN-2 EITHER ALONE OR IN COMBINATION WITH INTERFERON-ALFA-2B IN ADVANCED RENAL-CELL CARCINOMA [J].
ATKINS, MB ;
SPARANO, J ;
FISHER, RI ;
WEISS, GR ;
MARGOLIN, KA ;
FINK, KI ;
RUBINSTEIN, L ;
LOUIE, A ;
MIER, JW ;
GUCALP, R ;
SOSMAN, JA ;
BOLDT, DH ;
DOROSHOW, JH ;
ARONSON, FR ;
SZNOL, M .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (04) :661-670
[3]  
ATZPODIEN J, 1995, WORLD J UROL, V13, P174
[4]  
ATZPODIEN J, 1991, SEMIN ONCOL, V18, P108
[5]   MULTIINSTITUTIONAL HOME-THERAPY TRIAL OF RECOMBINANT HUMAN INTERLEUKIN-2 AND INTERFERON ALFA-2 IN PROGRESSIVE METASTATIC RENAL-CELL CARCINOMA [J].
ATZPODIEN, J ;
HANNINEN, EL ;
KIRCHNER, H ;
BODENSTEIN, H ;
PFREUNDSCHUH, M ;
REBMANN, U ;
METZNER, B ;
ILLIGER, HJ ;
JAKSE, G ;
NIESEL, T ;
SCHOLZ, HJ ;
WILHELM, S ;
PIELMEIER, T ;
ZAKRZEWSKI, G ;
BLUM, G ;
BEIER, J ;
MULLER, GW ;
DUENSING, S ;
ANTON, P ;
ALLHOFF, E ;
JONAS, U ;
POLIWODA, H .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (02) :497-501
[6]  
ATZPODIEN J, 1997, P ASCO, P1164
[7]   A Phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma [J].
Berg, WJ ;
Schwartz, LH ;
Amsterdam, A ;
Mazumdar, M ;
Vlamis, V ;
Law, TM ;
Nanus, DM ;
Motzer, RJ .
INVESTIGATIONAL NEW DRUGS, 1997, 15 (04) :353-355
[9]   Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients [J].
Bordin, V ;
Giani, L ;
Meregalli, S ;
Bukovec, R ;
Vaghi, MM ;
Mandalà, M ;
Paolorossi, F ;
Ardizzoia, A ;
Tancini, G ;
Barni, S ;
Frigerio, F ;
Fumagalli, L ;
Bordoni, A ;
Valusani, G ;
Di Felice, G ;
Lissoni, P .
UROLOGIA INTERNATIONALIS, 2000, 64 (01) :3-8
[10]  
BRETHEAU D, 1995, EUR UROL, V27, P319